News | Antiplatelet and Anticoagulation Therapies | November 01, 2018

Experimental Vaccine May Reduce Post-Stroke Blood Clot Risk

Vaccine was found to be as safe and effective as one of the most widely used oral blood thinners currently used to reduce clotting risk

Experimental Vaccine May Reduce Post-Stroke Blood Clot Risk

November 1, 2018 — A vaccine may one day be able to replace oral blood thinners to reduce the risk of secondary strokes caused by blood clots, without increasing the risk of serious bleeding or triggering an autoimmune response. These conclusions are drawn from new research in the American Heart Association’s journal Hypertension.1

People who have had a stroke caused by a blood clot (ischemic strokes) often need to take medications that make their blood less likely to clot, which helps prevent another stroke.

Japanese researchers successfully tested an experimental vaccine in mice and found that it provided protection against blood clots for more than two months, without increasing the risk of bleeding or causing an autoimmune response. The lack of an autoimmune response is important, because it means the mice’s immune system did not perceive the vaccine as an “intruder” that needed to be attacked, which would have caused a reaction to the vaccine.

The vaccine, S100A9, inhibits blood clot formation and, during the study, protected the arteries of treated mice from forming new clots for more than two months. Additionally, it worked as well as the oral blood thinner clopidogrel in a major artery, according to Hironori Nakagami, M.D., Ph.D., study co-author and professor at Osaka University in Japan.

Developing a vaccine to replace and/or compliment daily, oral medications might save many lives and help prevent both secondary strokes and possibly heart attacks, according to Nakagami.

“Many stroke patients don’t take their blood thinning drugs as prescribed, which makes it more likely they will have another stroke. This vaccine might one day help solve this issue since it would only need to be injected periodically,” Nakagami said.

“We are continuing our research in hopes of being able to start clinical trials between five and ten years from now, but there are differences between mice and humans in how the vaccine will be recognized by the immune system,” he said. “We should be able to overcome such problems and believe this vaccine provides a very promising strategy in secondary prevention of stroke.”

For more information: www,ahajournals.org/journal/hyp

 

Reference

1. Kawano T., Shimamura M., Nakagami H., et al. Therapeutic Vaccine Against S100A9 (S100 Calcium-Binding Protein A9) Inhibits Thrombosis Without Increasing the Risk of Bleeding in Ischemic Stroke in Mice. Hypertension, Oct. 29, 2018. doi/10.1161/HYPERTENSIONAHA.118.11316

Related Content

Study Finds Only Six Percent of Patients Taking Statins as Directed
News | Antiplatelet and Anticoagulation Therapies | April 18, 2019
A recent study found patients with atherosclerotic cardiovascular disease cut their risk of a second major adverse...
HonorHealth Research Institute Launches SynIVUS-DAPT Study
News | Antiplatelet and Anticoagulation Therapies | April 16, 2019
HonorHealth Research Institute announced the first patients have been enrolled in the SynIVUS-DAPT Study. The clinical...
Lack of Physician Guidance, Fear of Side Effects Influence Statin Compliance
News | Antiplatelet and Anticoagulation Therapies | April 15, 2019
Despite national guidelines indicating statins can lower risk of heart attack and stroke, many patients who could...
Stopping DAPT After One Month Improved Outcomes in Stent Patients
News | Antiplatelet and Anticoagulation Therapies | March 25, 2019
Patients who stopped taking aspirin one month after receiving a stent in the heart’s arteries but continued taking the...
Apixaban Effective in Specific Cohort of Non-Valvular Atrial Fibrillation Patients
News | Antiplatelet and Anticoagulation Therapies | March 19, 2019
The Bristol-Myers Squibb-Pfizer Alliance announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis (apixaban...
Researchers Develop Reversible, Drug-Free Antiplatelet Therapy
News | Antiplatelet and Anticoagulation Therapies | February 19, 2019
A new reversible, drug-free antiplatelet therapy could reduce the risk of blood clots and potentially prevent cancer...
FDA Approves Portola Pharmaceuticals' Prior Approval Supplement for Andexxa Generation 2 Manufacturing Process
News | Antiplatelet and Anticoagulation Therapies | January 02, 2019
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals’ Prior Approval Supplement (PAS) for...
Daily Aspirin Use May Do More Harm Than Good for Healthy People
News | Antiplatelet and Anticoagulation Therapies | December 17, 2018
Among otherwise healthy people, a daily dose of aspirin does not save lives and causes additional bleeding, a new...
Thrombolytic Science Initiates Phase 2 Trial of Novel Ischemic Stroke Treatment Regimen
News | Antiplatelet and Anticoagulation Therapies | September 07, 2018
A new Phase 2 clinical trial looks to confirm the efficacy and safety of Thrombolytic Science LLC’s (TSI) sequential...
Overlay Init